Bryce Point Capital LLC Takes Position in Omnicell, Inc. (NASDAQ:OMCL)

Bryce Point Capital LLC bought a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,054 shares of the company’s stock, valued at approximately $492,000.

Other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its holdings in shares of Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after purchasing an additional 273 shares during the last quarter. Van ECK Associates Corp boosted its stake in Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares during the last quarter. Headlands Technologies LLC purchased a new position in Omnicell during the 4th quarter valued at approximately $53,000. First Horizon Advisors Inc. increased its stake in Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after acquiring an additional 355 shares during the last quarter. Finally, Huntington National Bank increased its stake in Omnicell by 236.4% in the 4th quarter. Huntington National Bank now owns 1,359 shares of the company’s stock worth $61,000 after acquiring an additional 955 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on OMCL. Wells Fargo & Company cut their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Bank of America dropped their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Benchmark restated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a report on Monday, March 24th. Finally, JPMorgan Chase & Co. reduced their price objective on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, March 20th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Omnicell has an average rating of “Hold” and a consensus target price of $51.00.

Omnicell Stock Performance

Shares of NASDAQ:OMCL opened at $34.04 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.75. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of 126.08, a PEG ratio of 7.53 and a beta of 0.85. The firm’s 50-day moving average is $38.38 and its 200 day moving average is $42.35.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Research analysts predict that Omnicell, Inc. will post 1.09 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.